This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|March 13, 2014
Texas A&M Center Adds Mobile Cleanrooms
Author(s)BioPharm International Editors
Walker Barrier Systems builds eight mobile clean rooms for the Texas A&M Center for Innovation in Advanced Development and Manufacturing.
Advertisement
Walker Barrier Systems
, a producer of isolation and containment equipment, has built and delivered the first of eight mobile clean rooms for the Texas A&M Center for Innovation in Advanced Development and Manufacturing (CIADM).
The Texas A&M Center for Innovation is home to the National Center for Therapeutics Manufacturing (NCTM), which provides a facility for the development and production of vaccines and therapeutics for use in clinical trials. The addition of eight new mobile clean rooms to theNCTM will increase the development and manufacturing capacity of the CIADM.
The Walker Barrier Systems mobile clean room design will allow the NCTM to manufacture clinical grade materials at increased levels of compliance. Walker Barrier Systems units are built to support a wide range of processes and platforms that will be required by CIADM to manufacture biosecurity medical countermeasures.
Construction of the mobile clean rooms began in May 2013, and all eight are expected to be in operation at the NCTM by early 2014. The first unit was delivered in January 2014.
Source:
Walker Barrier Systems
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
3
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
4
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
5